Scope of US Patent 12,061,183: albumin/rapamycin nanoparticle quality-as-suitability methods and batch validation claims

US Patent 12,061,183 claims analytical methods and batch release/validation methods tied to a specific rapamycin-albumin nanoparticle system. The inventive core is a “suitability” determination for human medical use based on quantitative characterization of the albumin molecular species distribution on nanoparticles (polymers/monomers/dimers/oligomers), paired with optional control points for albumin coating amount, albumin:rapamycin ratio, cryo-TEM coating thickness, solubility in 5% human albumin, rapamycin crystallinity (non-crystalline), rapamycin recovery after 0.2 µm filtration, and post-storage testing, with optional binding-affinity measurements.

Below is the claim scope mapped to practical IP coverage, likely infringement theories (direct and induced), and a landscape view of adjacent patent estate themes for rapamycin-albumin nanoparticle formulations.

What does US 12,061,183 claim: albumin polymer/monomer thresholds for rapamycin-albumin nanoparticle suitability?

Independent method claims (claims 1 and 2)

Claim 1 (albumin polymers on nanoparticles)

Method for assessing suitability of a pharmaceutical composition for medical use in a human.
Composition: nanoparticles comprising rapamycin coated with albumin, plus a non-nanoparticle portion comprising albumin and rapamycin.
Key parameter: determine weight percentage of albumin polymers among the albumin on the nanoparticles.
Suitability indicator: 15% to 40% albumin polymers.

Claim 2 (albumin monomers on nanoparticles)

Same overall composition structure (rapamycin-albumin nanoparticles + non-nanoparticle albumin/rapamycin fraction).
Key parameter: determine weight percentage of albumin monomers among the albumin on the nanoparticles.
Suitability indicator: 40% to 60% albumin monomers.

These are not broad “rapamycin nanoparticle” claims. They are measurement-driven method claims with explicit threshold windows for albumin molecular species distribution on the nanoparticle fraction, which means infringement hinges on:

using the claimed composition structure, and
performing or using a method that determines the specified distribution and deems suitability based on the recited ranges.

Dependent claims add measurement or complementary control points

The claim set then layers additional determinants either as required steps (when dependent) or as optional further steps (where drafted as “further comprising”).

Key clusters:

Additional species distributions: monomers (claim 3), dimers (claim 14), oligomers (claim 15).
Total albumin and loading relationships: weight % albumin in nanoparticles (claim 4), albumin:rapamycin weight ratio in nanoparticles (claim 5).
Physical structure: coating thickness under cryo-TEM (claim 6).
Functional performance tests:
- solubility in 5% human albumin solution (claim 7),
- non-crystallinity / crystallinity state (claim 8),
- rapamycin recovery after 0.2 µm filtration (claim 9),
- solubility/crystallinity/recovery after storage (claim 10).
Crystallinity measurement modalities: X-ray diffraction, polarized light microscopy, or both (claim 11).
Binding affinity determination methods: equilibrium dialysis, FTIR, NMR (claim 12-13).
Chromatography modality for monomers: size-exclusion chromatography (claim 16).

Commercial batch claims transform the method into validated batch release

Claims 17 and 18 are “commercial batch” claims:

The batch contains the same composition structure (albumin-coated rapamycin nanoparticles + non-nanoparticle portion).
The batch is validated by assessing suitability according to claim 1 or claim 2, respectively.

This is a direct hook into manufacturing and quality operations: validation procedures tied to the claimed analytical windows can create infringement exposure for parties conducting batch validation.

How broad are the claims in US 12,061,183: what is covered vs. what is not?

Covered: analytical suitability based on albumin species distribution on nanoparticle-associated albumin

The strongest and most central restriction is the recited metric:

albumin polymers weight % among albumin on nanoparticles (15%–40%) and/or
albumin monomers weight % among albumin on nanoparticles (40%–60%).

This can be interpreted as targeting a specific quality attribute of albumin conformation/aggregation state associated with the nanoparticle surface and/or nanoparticle-associated albumin fraction.

Covered: the composition includes both nanoparticle and non-nanoparticle fractions

Each independent claim requires:

nanoparticles comprising rapamycin coated with albumin, and
a non-nanoparticle portion comprising albumin and rapamycin.

So a composition that has only nanoparticle-associated albumin with no “non-nanoparticle portion” would be outside the literal claim structure, unless the formulation still contains a fraction that qualifies as non-nanoparticle portion under how the patent defines/operationalizes it (the independent claims themselves include the phrase “comprises… and a non-nanoparticle portion…”).

Covered: threshold ranges and test methods are tied to “suitability”

The ranges function like a gatekeeping construct. A party whose assay results land outside the thresholds would avoid the “indicative of suitability” element if they do not treat the composition as suitable on those grounds.

However, parties may still face risk if they:

run the method,
obtain results in the ranges, and
treat the formulation as suitable for human medical use using those criteria.

Not covered (or substantially narrowed):

If rapamycin is not the drug in the nanoparticles, or albumin is not the coating, the core structural element fails.
If the “albumin on the nanoparticles” distribution is not measured (or if suitability is not assessed using the recited thresholds), method-claim infringement becomes harder.
If crystallinity is not “non-crystalline” (claim 8) or the specific filtration recovery threshold is not met (claim 9), those dependent features would not be met, assuming they are treated as required steps by the relevant asserted dependent claims.

What is the technical meaning of the “albumin polymers/monomers” thresholds and how does it impact infringement risk?

Operational risk points

For infringement (especially for dependent claims) the key operational question is how “albumin polymers,” “monomers,” “dimers,” and “oligomers” are defined and quantified on “albumin on the nanoparticles.” The patent text you provided indicates:

monomers can be determined by size-exclusion chromatography (claim 16),
other fraction determinations are recited by weight % but not always tied to a specific assay method in your excerpts.

If an accused process uses a different separation scheme that does not map onto the patent’s definitions, noninfringement arguments may arise. But where the accused process uses size-exclusion chromatography and obtains weight distributions that fall within the claimed windows, the fit is stronger.

Where defendants are likely to focus

Whether the relevant fraction is “on the nanoparticles” vs. in the bulk.
How nanoparticle separation/partitioning is done before assay.
Whether the assay is intended to determine the weight % of monomers/polymers among “albumin on the nanoparticles.”
Whether batch release relies on those thresholds as “indicative of suitability.”

Why the claims are powerful

The use of a quality attribute tied to analytical quantification makes the claims less dependent on how the nanoparticles are manufactured internally and more dependent on the measurable state of the final material and the validation logic applied to release for human use.

Which dependent claim features materially narrow coverage: solubility, crystallinity, filtration recovery, cryo-TEM thickness, and binding affinity?

Albumin quantity and loading

Claim 4: weight % albumin in nanoparticles 15%–30%.
Claim 5: albumin:rapamycin weight ratio in nanoparticles 1:2 to 1:6. These are formulation composition constraints likely to track production settings (albumin loading and drug loading).

Nanoparticle coating morphology

Claim 6: albumin coating thickness under cryo-TEM 5 nm to 7 nm.

This suggests a control strategy that ties product quality to observed physical thickness.

Drug solubility performance in albumin solution

Claim 7: solubility 50 µg/mL to 100 µg/mL in 5% human albumin solution.

This is a functional performance criterion tied to drug release and interaction with albumin.

Crystallinity control

Claim 8: rapamycin crystallinity: a non-crystalline state is indicative of suitability.
Claim 11: crystallinity determined by X-ray diffraction, polarized light microscopy, or both.

This narrows claims where non-crystallinity is required as a suitability indicator.

Filtration stability / recovery

Claim 9: rapamycin recovery following 0.2 µm filtration is at least 80%.

A high recovery implies retention of drug in soluble/finely dispersed forms rather than losing drug through filtration.

Post-storage performance

Claim 10: determine solubility, crystallinity, or recovery after storage.

This connects the suitability attribute to shelf-life behavior.

Binding affinity measurement (optional but present in dependent claims)

Claim 12-13: binding affinity of albumin to rapamycin determined by:
- equilibrium dialysis,
- FTIR,
- NMR,
- or combinations.

If asserted as part of a dependent claim, infringement turns on using those measurement approaches, or at least on satisfying the dependent feature as claimed.

What formulations are protected: albumin-coated rapamycin nanoparticles with non-nanoparticle albumin/rapamycin fraction

The claims cover a formulation with:

nanoparticles: rapamycin coated with albumin, and
non-nanoparticle fraction: albumin and rapamycin not in nanoparticle form.

The inclusion of a non-nanoparticle portion suggests the formulation may be a mixed-state system: a nanoparticle dispersion plus soluble or differently sized components containing albumin and rapamycin.

Practical implication:

A competitor cannot design around the patent simply by changing nanoparticle size distributions if their composition still includes an albumin/rapamycin non-nanoparticle portion and the albumin species distribution on nanoparticles falls in the claimed windows.

When does US 12,061,183 expire and how do exclusivity and patent term factors affect generic entry?

The provided prompt includes only the claim text, not:

filing date, application number, priority dates,
patent grant date,
PTA/PTE,
terminal disclaimer status, or
whether this is a continuation.

Without those facts, the expiration schedule cannot be determined from the claim language alone.

What patent litigation or Paragraph IV risk exists for US 12,061,183?

The provided prompt includes no litigation docket, Orange Book listing, NDA/BLA number, or settlement history. Patent litigation exposure for a method-of-suitability claim and commercial batch validation claim typically arises via:

allegations of use in manufacturing validation,
counterclaims around whether an accused product is the same formulation state and whether assays match claim requirements.

But specifics cannot be produced from claim text alone.

What is the Orange Book status of US 12,061,183 and which FDA product is it tied to?

No Orange Book information (listed drug, NDA number, application holder, dosage form, approval date) is provided in the prompt.

So the Orange Book status cannot be mapped here to:

an approved drug product,
a listed active ingredient strength,
and the “method of assessing suitability” being used for batch release under current GMP.

How does US 12,061,183 compare with other albumin-drug nanoparticle patent themes (scope gaps competitors can exploit)?

Likely adjacent themes in the rapamycin-albumin nanoparticle space

Even without enumerating specific patent numbers, the claim set indicates the patent is positioned around:

Albumin structural state/conformation distribution (monomers/polymers/dimers/oligomers).
Product stability and performance criteria (non-crystalline rapamycin; recovery after filtration; solubility in albumin solution; post-storage).
Morphological characterization (cryo-TEM thickness).
Binding affinity characterization (equilibrium dialysis/FTIR/NMR).

Competitors can attempt design-around strategies that target one or more of these categories:

shift albumin species distribution so monomers or polymers fall outside thresholds,
adjust formulation so rapamycin becomes crystalline (if acceptable for safety/efficacy) or reduces to non-qualifying states,
modify nanoparticle coating characteristics so cryo-TEM thickness falls outside 5–7 nm,
alter the filtration recovery so rapamycin recovery after 0.2 µm drops below 80%,
change the formulation to eliminate the “non-nanoparticle portion comprising albumin and rapamycin,” if feasible.

However, since the claims explicitly tie suitability to these measured attributes, the most practical risk arises where competitors adopt the same or similar analytical controls and fall into the same windows.

How many claims drive infringement exposure: where in the chain of commerce is liability most likely?

Manufacturing and quality control are the high-probability touchpoints

Claims 17–18 cover a “commercial batch” validated by assessing suitability according to claims 1 or 2.
This is aligned with GMP activities:
- in-process checks,
- release testing,
- stability testing.

Method performance by third parties

If an accused manufacturer outsources analytics or stability testing to a contract lab, the labs may perform steps of the method while the manufacturer decides batch suitability. Method-claim theories often focus on whether the party accused “uses” the method by integrating the assay into suitability decision-making.

Key claim-to-attribute map (actionable for freedom-to-operate analysis)

Claim	Formulation structure element	Main suitability attribute(s)	Indicative range / condition
1	Rapamycin nanoparticles coated with albumin + non-nanoparticle albumin/rapamycin portion	Albumin polymers % among albumin on nanoparticles	15%–40%
2	Same structure	Albumin monomers % among albumin on nanoparticles	40%–60%
3	Depends on claim 2	Also requires monomers window	40%–60%
4	Depends on claim 2	Albumin wt% in nanoparticles	15%–30%
5	Depends on claim 2	Albumin:rapamycin wt ratio in nanoparticles	1:2–1:6
6	Depends on claim 2	Coating thickness under cryo-TEM	5–7 nm
7	Depends on claim 2	Solubility in 5% human albumin solution	50–100 µg/mL
8	Depends on claim 2	Rapamycin crystallinity	non-crystalline state
9	Depends on claim 2	Rapamycin recovery after 0.2 µm filtration	≥80%
10	Depends on claim 2	Tests after storage	after storage
11	Depends on claim 8	Crystallinity assay methods	XRd, polarized light microscopy, or both
12	Depends on claim 2	Binding affinity of albumin to rapamycin	determined (method optional)
13	Depends on claim 12	Binding affinity assay modalities	equilibrium dialysis, FTIR, NMR, or combination
14	Depends on claim 2	Albumin dimers % among albumin on nanoparticles	15%–30%
15	Depends on claim 2	Albumin oligomers % among albumin on nanoparticles	7%–15%
16	Depends on claim 2	Determination of monomers by size-exclusion chromatography	monomers by SEC
17	Commercial batch validated per claim 1	Suitability under claim 1	batch validated using polymers window
18	Commercial batch validated per claim 2	Suitability under claim 2	batch validated using monomers window

Patent strength assessment: how enforceable is this kind of “quality attribute suitability” claim set?

Strength factors

Explicit, quantitative windows: easier to map to assay results.
Direct linkage to “commercial batch” validation: targets routine manufacturing QA workflows.
Multiple dependent features allow alternative claim paths in litigation: if a defendant can move off one attribute window, an asserted dependent claim may still be satisfied.

Litigation pressure points

Infringement disputes will likely focus on assay definition and measurement: what counts as “albumin on nanoparticles,” how it is separated, and whether the measured distributions map to the claim categories.
Validity challenges often target whether the ranges and species definitions are sufficiently supported and whether the claims are obvious in view of prior albumin conformation and rapamycin nanoparticle approaches. Without the specification and file history, those cannot be evaluated here.

Key Takeaways

US Patent 12,061,183 centers on method claims for assessing suitability of a rapamycin-albumin nanoparticle formulation by measuring albumin molecular species distribution on nanoparticles, with standout windows at 15%–40% albumin polymers (claim 1) and 40%–60% albumin monomers (claim 2).
The formulation claim structure requires both nanoparticle and non-nanoparticle albumin/rapamycin components, tightening scope against nanoparticle-only dispersions.
Dependent claims expand coverage through specific formulation and performance attributes: albumin loading (wt% and ratio), cryo-TEM thickness (5–7 nm), solubility (50–100 µg/mL in 5% human albumin), non-crystalline rapamycin, 0.2 µm filtration recovery (≥80%), and post-storage testing.
Claims 17–18 convert the method into commercial batch validation coverage, creating higher likelihood of manufacturing-side infringement allegations.
A meaningful freedom-to-operate assessment should treat the patent as an analytical-quality and release-criteria IP asset, not a generic “rapamycin nanoparticle” formulation patent.

FAQs

1) Does US 12,061,183 cover just the nanoparticle formulation or also mixed nanoparticle and soluble fractions?
It requires both: nanoparticles coated with albumin and a non-nanoparticle portion comprising albumin and rapamycin.

2) If a competitor measures albumin monomers but does not use the 40%–60% suitability criterion for human use, is there infringement risk?
Risk is tied to “assessing suitability” using the recited indicative window; avoiding that decision logic can reduce method-claim fit.

3) Which assay platforms are explicitly called out in the claims?
Size-exclusion chromatography for monomers (claim 16), cryo-TEM for coating thickness (claim 6), X-ray diffraction and/or polarized light microscopy for crystallinity (claim 11), and equilibrium dialysis/FTIR/NMR for binding affinity (claim 13).

4) Can the patent be implicated even if the product is therapeutically similar but not measured to match the albumin species windows?
Infringement is likely to require assay results and suitability assessments matching the windows (polymers 15%–40% or monomers 40%–60%, plus any asserted dependent features).

5) Are batch release and validation specifically within scope?
Yes. Claims 17–18 cover a commercial batch validated by performing suitability assessment under claims 1 or 2.

References (APA)

US Patent 12,061,183, claims 1–18 (provided claim text).

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Aadi	FYARRO	sirolimus	POWDER;INTRAVENOUS	213312-001	Nov 22, 2021		RX	Yes	Yes	12,061,183	⤷ Start Trial	Y				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Summary for Patent: 12,061,183